Miyamura Tatsuo, Kanda Tatsuo, Nakamoto Shingo, Arai Makoto, Nakamura Masato, Wu Shuang, Jiang Xia, Sasaki Reina, Haga Yuki, Yasui Shin, Ooka Yoshihiko, Chiba Tetsuhiro, Imazeki Fumio, Mikami Shigeru, Yokosuka Osamu
Departments of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan.
Department of Molecular Virology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan.
Int J Hepatol. 2014;2014:723868. doi: 10.1155/2014/723868. Epub 2014 Dec 8.
Aim. Eradication of hepatitis C virus (HCV) is still challenging even if interferon- (IFN-) free regimens with direct-acting antiviral agents (DAAs) for HCV-infected individuals are available in clinical practice. IFNL4 is a newly described protein, associated with human antiviral defenses. We investigated whether IFNL4 ss469415590 variant has an effect on the prediction of treatment response in HCV-infected patients treated with IFN-including regimens. Patients and Methods. In all, 185 patients infected with HCV genotype 1 treated with peg-IFN plus ribavirin, with or without telaprevir, were genotyped for IFNL4 ss469415590. We retrospectively investigated whether the role of IFNL4 ss469415590 variant and other factors could predict sustained virological response (SVR) in Japanese patients infected with HCV genotype 1. Results. There were 65.7%, 31.5%, and 2.8% patients in the IFNL4 ss469415590 TT/TT, TT/-G, and -G/-G groups, respectively. SVR rates were 82.1% or 49.3% in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Conclusion. In the era of DAAs, measurement of IFNL4 ss469415590 variant could help the prediction of SVR in Japanese HCV genotype 1 infected individuals treated with IFN-including regimens.
目的。即使在临床实践中已有用于丙型肝炎病毒（HCV）感染者的不含干扰素（IFN）的直接抗病毒药物（DAA）方案，但根除HCV仍然具有挑战性。IFNL4是一种新描述的蛋白质，与人类抗病毒防御相关。我们研究了IFNL4 ss469415590变体对接受含IFN方案治疗的HCV感染患者治疗反应预测是否有影响。患者与方法。总共185例感染HCV 1型且接受聚乙二醇干扰素联合利巴韦林治疗（无论是否联合特拉匹韦）的患者进行了IFNL4 ss469415590基因分型。我们回顾性研究了IFNL4 ss469415590变体及其他因素能否预测日本HCV 1型感染患者的持续病毒学应答（SVR）。结果。IFNL4 ss469415590 TT/TT、TT/-G和-G/-G组的患者分别占65.7%、31.5%和2.8%。接受聚乙二醇干扰素联合利巴韦林治疗（无论是否联合特拉匹韦）的患者SVR率分别为82.1%或49.3%。IFNL4 ss469415590变体与HCV病毒载量或IFNL4 ss469415590变体与早期病毒学应答分别是接受聚乙二醇干扰素联合利巴韦林治疗（无论是否联合特拉匹韦）患者SVR的更好预测指标。结论。在DAA时代，检测IFNL4 ss469415590变体有助于预测接受含IFN方案治疗的日本HCV 1型感染个体的SVR。
